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Abstract
There are 91 known capsular serotypes of Streptococcus pneumoniae. The nasopharyngeal carriage prevalence of particular
serotypes is relatively stable worldwide, but the host and bacterial factors that maintain these patterns are poorly
understood. Given the possibility of serotype replacement following vaccination against seven clinically important
serotypes, it is increasingly important to understand these factors. We hypothesized that the biochemical structure of the
capsular polysaccharides could influence the degree of encapsulation of different serotypes, their susceptibility to killing by
neutrophils, and ultimately their success during nasopharyngeal carriage. We sought to measure biological differences
among capsular serotypes that may account for epidemiological patterns. Using an in vitro assay with both isogenic
capsule-switch variants and clinical carriage isolates, we found an association between increased carriage prevalence and
resistance to non-opsonic neutrophil-mediated killing, and serotypes that were resistant to neutrophil-mediated killing
tended to be more heavily encapsulated, as determined by FITC-dextran exclusion. Next, we identified a link between
polysaccharide structure and carriage prevalence. Significantly, non-vaccine serotypes that have become common in
vaccinated populations tend to be those with fewer carbons per repeat unit and low energy expended per repeat unit,
suggesting a novel biological principle to explain patterns of serotype replacement. More prevalent serotypes are more
heavily encapsulated and more resistant to neutrophil-mediated killing, and these phenotypes are associated with the
structure of the capsular polysaccharide, suggesting a direct relationship between polysaccharide biochemistry and the
success of a serotype during nasopharyngeal carriage and potentially providing a method for predicting serotype
replacement.
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Introduction
Streptococcus pneumoniae, or pneumococcus, is an important
pathogen worldwide and is a causative agent of pneumonia,
meningitis and otitis media. There are 91 known pneumococcal
serotypes, and each produces a biochemically distinct polysaccha-
ride capsule that is in most cases covalently attached to the cell
wall. Serotype affects nearly every aspect of pneumococcal
pathogenesis and of nasopharyngeal carriage, which precedes
disease and serves as the reservoir for transmission of the organism
[1]. The serotypes most common in both invasive disease [2,3] and
carriage [4] show remarkable consistency across geography and
time despite some differences in the details. Serotypes differ not
only in their prevalence, but also in their tendency to cause
invasive or mucosal disease (ratio of disease cases to carriers) [5–8],
their age distribution [4], their tendency to cause outbreaks [4,9],
and their degree of antimicrobial resistance [10].
The polysaccharide-protein pneumococcal conjugate vaccine
(Prevnar, or PCV7) targets seven clinically relevant serotypes in
young children. Currently, the vaccine is in widespread use, and
while PCV7 has been largely successful at reducing the burden of
invasive pneumococcal disease in the United States. [11], evidence
is emerging that serotypes not targeted by the vaccine, such as
types 19A and 15, are increasing in importance in both carriage
and invasive disease [12–15]. In the long-term, disease caused by
replacement serotypes could partially undermine the impact of the
vaccine. As more countries introduce PCV7 or explore alternative
polysaccharide formulations, it will be critical to understand the
factors that determine serotype patterns of carriage. We sought to
measure the biological differences among capsular serotypes that
may account for these effects on pneumococcal epidemiology and
then use these biological measures as predictors of prevalence
before and after vaccination.
Duration of carriage, a determinant of prevalence, varies
between serotypes [16,17] and could, in part, be influenced by the
interactions between bacteria and host immune effectors. The
capsule protects against phagocytic clearance by blocking the
deposition and function of opsonins directed against cell surface
antigens [18–20]. In addition, capsule can affect susceptibility to
trapping by neutrophil extracellular traps (NETs) [21], killing by
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more capsule in vitro are more virulent in vivo [24], but degree of
encapsulation has not previously been shown to strongly impact
nasopharyngeal colonization [25].
Immune-mediated clearance from the nasopharynx involves
both antibody-dependent and antibody-independent mechanisms
of immunity [26–29]. Antibody-independent clearance is thought
to involve an IL-17A-mediated T-cell response [30,31], which
results in the recruitment of neutrophils to the site of infection and
subsequent clearance of colonization [31,32]. Neutrophils can kill
pneumococci in the presence or absence of opsonins, and heavily
encapsulated strains can avoid phagocytic uptake [33–36].
Capsular polysaccharide quantity and degree of encapsulation
could be influenced by a number of factors, and recent work has
demonstrated that sugar metabolism could play a regulatory role
[37,38]. We hypothesized that serotypes that require more energy
or carbon to synthesize a polysaccharide repeat unit would
ultimately have smaller, less inhibitory capsules. In this study, we
demonstrate an association between polysaccharide structure,
degree of encapsulation, susceptibility to neutrophil-mediated
killing, and carriage prevalence. We propose a model in which
serotypes that produce metabolically inexpensive polysaccharides
will be more heavily encapsulated, which in turn allows them to
persist in the nasopharynx for a longer duration and results in
higher prevalence. These results will be particularly useful in
predicting the impact of serotype-replacement in various settings.
Results
Capsule protects against non-opsonic killing by human
neutrophils
First, we evaluated whether the production of a capsule affected
susceptibility to opsonin-independent killing by human neutro-
phils. We tested an invasive type 6B clinical isolate, its
unencapsulated isogenic derivative and the reconstituted strain
with the type 6B capsule locus reinserted. The wild type and the
reconstituted encapsulated strain were significantly more resistant
to killing than the unencapsulated mutant (Figure 1A). Addition-
ally, by flow cytometry we found that the unencapsulated strain
was more efficiently associated with neutrophils than the wild type
or the reconstituted strain (Figure 1B).
Resistance to killing correlates with higher carriage
prevalence
To test whether highly prevalent serotypes are more resistant to
neutrophil-mediated killing, we used a panel of TIGR4 capsule-
switch variants that are isogenic except for the capsule locus. The
more prevalent serotypes, such as 19F and 23F, were indeed most
resistant to killing, while types that are rarely isolated from
carriage, such as types 4 and 5, were more efficiently killed
(r=0.77, p,0.001; Figure 1C).
To confirm these results, we tested another set of five isogenic
capsule-switch variants that were constructed in strain 603, a type
6B clinical isolate. Again, we found that resistance to neutrophil-
mediated killing was associated with higher carriage prevalence
(Figure S1). The serotype rank-order of susceptibility to killing was
the same in both sets of isogenic capsule-switch variants with the
exception of type 6B, which was more resistant to killing in the 603
genetic background.
Capsule type affects resistance to killing in diverse
genetic backgrounds
To determine whether the effect of serotype on avoidance of
neutrophil-mediated killing could be generalized to clinical
carriage isolates, we tested a set of strains from diverse bacterial
genetic backgrounds. There was a significant association between
susceptibility to killing of the TIGR4 isogenic capsule variants and
the corresponding clinical strain of the same serogroup (Figure 1D).
These results indicate that serotype is a major determinant of
resistance to neutrophil-mediated killing in diverse genetic
backgrounds, though it is not the only determining factor.
Resistance to killing is related to degree of encapsulation
We next wanted to evaluate whether differences in degree of
encapsulation between serotypes could affect interactions with
neutrophils. To determine the degree of encapsulation, we
measured the zone of exclusion of fluorescent dextran molecules
by the capsule [39] using our isogenic TIGR4 capsule-switch
variants. Serotype significantly influenced the size of the zone of
dextran exclusion, and types with larger zones of exclusion were
more resistant to neutrophil-mediated killing and more prevalent
in carriage (Figure 2). Serotypes that had large zones of dextran
exclusion also had clearly visible capsules when suspended in India
ink (Figure S2). We also found that pre-incubating the neutrophils
with purified capsular polysaccharides had no effect on neutrophil-
mediated killing (data not shown), further suggesting that the
capsule is blocking the bacterial surface from the neutrophils
rather than being itself a target.
These correlations suggest that degree of encapsulation affects
resistance to neutrophil-mediated killing. However, given the
differences in structure between polysaccharides, it is possible that
some other structural feature, which happens to be correlated with
degree of encapsulation, is actually the mechanism of differential
resistance to killing. To test the hypothesis that degree of
encapsulation is the relevant measure, we made comparisons
within a serotype, where structure should be conserved but degree
of encapsulation could be manipulated by changing carbon
sources, as previously reported [40,41]. A derivative of TIGR4
producing a type 19F capsule was grown in a semi-defined
medium with either fructose, which has been reported to reduce
capsule production [41], or glucose. We found that bacteria grown
in fructose were less encapsulated than those grown in glucose,
both by India Ink microscopy (Figure 3C,D) and by capsular
polysaccharide inhibition ELISA (Figure 3A). Significantly,
fructose-grown bacteria were more susceptible to surface killing,
Author Summary
Streptococcus pneumoniae, or pneumococcus, is an impor-
tant pathogen worldwide and causes a wide range of
diseases, mostly inyoung childrenandtheelderly. There are
91 serotypes of pneumococcus, each of which produces a
unique polysaccharide, called the capsule, that attaches to
the bacterial surface and prevents it from being cleared by
the host. The serotypes differ greatly in their prevalence in
thehumanpopulation.Thereiscurrently avaccine,effective
in infancy, which targets seven clinically important sero-
types, but several types not covered by the vaccine are
beginning to increase in carriage frequency. As a result, it is
critical to understand why some serotypes are frequently
carried inthe human population whileothersare not. In this
study, we find that the high-prevalence serotypes tend to
be more heavily encapsulated and more resistant to killing
by neutrophils. Significantly, we find that the biochemical
properties of the different polysaccharides can be used to
predict their carriage frequency both before and after
introduction of the vaccine. These results provide a
biologically plausible explanation for differences in preva-
lence between serotypes.
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growth in fructose (Figures 3B, S3). These results, which are
consistent with findings in group A Streptococcus [42], indicate that
degree of encapsulation directly affects susceptibility to non-
opsonic neutrophil-mediated killing.
Serotype affects colonization in vivo
Todeterminewhetherourinvitrofindingswereapplicable toanin
vivo situation, we co-colonized mice with a mix of isogenic TIGR4
capsule-switch variants producing type 14 and type 19F polysac-
charides. These serotypes were chosen because of their different
phenotypes in the in vitro assays and because they are easily
distinguishable by colony morphology on blood agar plates. In past
experiments, we have shown that both strains can colonize mice at
similar densities when inoculated alone. Based on our in vitro results,
we hypothesized that type 19F would out-compete type 14.
We intranasally inoculated mice with a ratio of 100 CFU of
type 14 to 1 CFU of type 19F (proportion 19F=0.01). Consistent
with our hypothesis, while only 1% of the inoculum was type 19F,
90% of the colonies recovered from the nasal washes after 7 days
were type 19F, indicating that type 19F colonizes mice
significantly better than type 14 (4 mice, average proportion
19F: 0.90, SEM: 0.04, binomial probability: p,0.001 compared to
inoculum).
Polysaccharide structure is associated with prevalence,
degree of encapsulation, and neutrophil-mediated killing
Having found a relationship between prevalence and degree of
encapsulation and resistance to neutrophil-mediated killing, we
next wanted to evaluate bacterial factors that could influence these
phenotypes. We hypothesized that the extent of encapsulation,
and subsequently the epidemiologic properties of the serotype,
Figure 1. Effect of serotype on resistance to non-opsonic killing by neutrophils. A) Capsule increases resistance of pneumococcus type 6B
to non-opsonic surface killing compared to an unencapsulated derivative. Mean+/2SEM from a representative experiment. p,0.001 B) Capsule
prevents association of pneumococcus type 6B with human PMNs. Mean+/2range from two independent experiments. MFI: Mean fluorescence
intensity of neutrophils. C) Avoidance of neutrophil-mediated killing by the TIGR4 capsule variants is directly correlated with the frequency of each
serotype among carriage isolates. Mean survival relative to serotype 9N is shown. r=0.78, p,0.01. D) Susceptibility to neutrophil-mediated killing is a
property of capsular type across diverse genetic backgrounds. Linear regression is shown comparing survival from neutrophil-mediated killing
between isogenic TIGR4 capsule variants and diverse clinical isolates. Mean+/2range., r=0.49, p,0.05.
doi:10.1371/journal.ppat.1000476.g001
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thesis of different capsular polysaccharides. By examining
published polysaccharide structures and biochemical pathways,
we determined the number of carbons and the number of high-
energy bonds (ATP-equivalents) that are required to generate one
polysaccharide repeat unit. Consistent with the hypothesis, we
found a significant association between these measures of
metabolic cost and degree of encapsulation and a trend between
metabolic cost and resistance to non-opsonic killing (Table 1).
Next, we evaluated the relationship between these correlates of
polysaccharide structure and carriage prevalence. We began by
assessing prevalence in populations not exposed to PCV7. Using
carriage data pooled from three studies in the United Kingdom,
the United States, and The Netherlands, we found a statistically
significant inverse correlation between metabolic cost and serotype
frequency among circulating types (Table 1, Figure 4). These
analyses were performed among serotypes with an average
frequency of at least 1%. As Figure 4 shows, serotypes that were
extremely rare (,1%) had a broad range of carbons per repeat
unit, suggesting that polysaccharide structure is not the sole
determinant of the success of a serotype, and in particular
suggesting that a low metabolic cost is necessary, but not sufficient
for high prevalence in unvaccinated populations. We noted that
serotype 3 – which has the least costly repeat unit structure and is
known for its mucoid colony phenotype that is attributed to
extensive capsule production – was an outlier in this relationship,
with relatively low carriage prevalence. While the reason for its
outlier status is unclear, it is notable that type 3 polysaccharide can
generate a relatively strong antibody response early in infancy
[43], and this serotype is highly clonal. Without serotype 3, the
relationships become much stronger (Table 1).
Finally, we evaluated the relationship between polysaccharide
structure and prevalence in a population exposed to PCV7, which
has opened an ecological niche for serotypes not included in the
vaccine. To date, no principle has been identified to predict which
non-vaccine serotypes would become most common in vaccinated
populations. We hypothesized that metabolic cost might provide
such a principle to predict which non-vaccine serotypes would
become most common in vaccinated populations. We compared
the prevalence of serotypes in a post-vaccine carriage sample in
Massachusetts in 2004 [12,44] to measures of metabolic cost.
Similar to what was seen before vaccination, there was no
distinctive pattern of metabolic cost among the serotypes with
frequencies ,1%, but among those at appreciable frequencies,
there was a negative relationship between metabolic cost and
prevalence (Figure 4B), albeit here not statistically significant
(Table 1). Once again, serotype 3 was an extreme outlier, and
exclusion of type 3 resulted in a strong association between
metabolic cost and prevalence (Table 1). We also found that
increased degree of encapsulation was itself associated with higher
post-vaccine carriage prevalence among the serotypes that we
tested (Figure S4).
Discussion
Our data suggest a novel biological explanation for serotype
patterns of pneumococcal carriage. If clearance of pneumococcus
from the nasopharynx depends on T-cell-mediated immunity
[28,31], we would expect that serotypes that successfully avoid
neutrophil-mediated killing will persist longer in the nasopharynx
(thereby also obtaining more opportunities for transmission) and,
as a result, be more prevalent in the population. Our results
demonstrate a clear link between capsular polysaccharide
structure and prevalence. We propose a model in which serotypes
producing polysaccharides that are less metabolically costly will be
more heavily encapsulated and thus avoid phagocytic clearance
and persist in carriage.
It is possible, though, that innate immune effectors in addition
to or instead of neutrophils could determine the serotype
prevalence hierarchy. In particular, phagocytes other than
neutrophils could play a role, and antimicrobial peptides [22],
mucus-mediated clearance [23], complement, C-reactive protein
[45], and antibodies directed against the capsule or other surface
antigens could all affect clearance rates of different serotypes from
the nasopharynx. Likewise, some of these factors could affect the
rate of acquisition of new carriage episodes, which would also
influence the prevalence of a serotype.
While interactions with the host likely play a large role in
shaping serotype patterns, polysaccharide production itself could
affect the fitness of the bacterium and thus its ability to compete
with other serotypes during colonization. We did not observe any
Figure 2. Relationship between degree of encapsulation,
resistance to neutrophil-mediated killing, and carriage preva-
lence. Capsule size, as evaluated by FITC-Dextran exclusion, is related
to A) avoidance of neutrophil-mediated killing (r=0.58, p,0.05) and B)
carriage prevalence (r=0.68, p,0.01). The mean area of the zone of
FITC-dextran exclusion, including the bacterial body and capsule, is
shown. 100–250 cells per serotype were measured, and the zone of
exclusion for unencapsulated TIGR4 was 286 pixels.
doi:10.1371/journal.ppat.1000476.g002
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but it is possible that under in vivo conditions, polysaccharide
production causes a competitive disadvantage for some serotypes.
It is also possible that our measures of ‘‘metabolic cost’’ do not
reflect the true cost to the bacteria since the organisms could
respond to environmental pressures by changing their carbon and
energy utilization.
Our findings provide a simple method for ranking serotype
prevalence. The currently available vaccine for infants targets
seven clinically relevant serotypes, but alternative formulations,
including 10- and 13-valent vaccines, are being explored for use in
developing countries. Since the relationship between polysaccha-
ride structure and serotype prevalence is observed in both
vaccinated and unvaccinated populations, this could potentially
be used as a tool for predicting patterns of serotype replacement in
different settings.
It has long been known that many characteristics of pneumo-
coccal epidemiology were associated with serotype. Here, using
two sets of pneumococci that are isogenic except for their capsular
serotypes, we have shown that an in vitro predictor of these
Figure 3. Effect of degree of encapsulation on susceptibility to neutrophil-mediated killing of type 19F. Growth in fructose leads to A) a
decrease in cell-associated type 19F polysaccharide as evaluated by inhibition ELISA and B) decreased resistance to neutrophil-mediated killing.
Mean+/2SEM, p,0.001. The capsules of bacteria grown in C) glucose or D) fructose were visualized in India ink.
doi:10.1371/journal.ppat.1000476.g003
Table 1. Relationship between capsular polysaccharide
composition, degree of encapsulation, neutrophil-mediated
killing, and prevalence.
Carbon High energy
Capsule Size 20.60
{ 20.70
{
Resistance to neutrophil killing 20.48 20.51
Pre-PCV7 frequency 20.73
{ 20.72
{
Pre-PCV7 frequency (excl type 3) 20.80
{{ 20.79
{{
Post-PCV7 frequency 20.40 20.31
Post-PCV7 frequency (excl type 3) 20.90
{ 20.88
{
The number of carbons or the number of high energy molecules consumed per
repeat unit is associated with capsule size, resistance to neutrophil-mediated
killing, and average serotype carriage frequency [17,44,64]. Post-PCV7
prevalence data (2004) was obtained from Hanage et al [44]. Spearman
correlation coefficients are shown,
{p,0.05,
{{p,0.001.
doi:10.1371/journal.ppat.1000476.t001
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determined in large part by capsular type rather than bacterial
genetic background; moreover, using multiple clinical isolates, we
have shown that these in vitro properties of different serotypes are
consistent across diverse genetic backgrounds. However, it is also
clear from our data that these in vitro properties can vary within
capsular serotypes, consistent with the possibility that noncapsular
factors, such as bacterial adhesins, could affect the success of a
strain during colonization and could subsequently influence
patterns of serotype replacement. Certain clones have been
particularly successful and have acquired multiple serotypes
[46,47], further supporting the notion that other genetic factors
influence the fitness of a pneumococcal strain. Likewise, while the
types that are present at appreciable frequencies show a negative
relationship between prevalence and metabolic cost, there are
many serotypes with low metabolic costs that remain rare, most
notably serotype 3. This finding suggests that a metabolically
inexpensive capsule is necessary, but not sufficient, for high
prevalence (Figure 4).
The mechanistic explanation for the association between
polysaccharide structure and degree of encapsulation remains to
be elucidated. We evaluated a number of structural features
including the number of particular monosaccharide units, number
of N-acetylated sugars and number and proportion of hydropho-
bic residues. One possibility is that limited supplies of energy or
carbon impose more stringent limits on the production of
metabolically costly capsule subunits than on the production of
less costly ones. Another possibility, not mutually exclusive, results
from the fact that serotypes with less costly polysaccharide repeat
units also tend to have a higher ratio of charged molecules per
carbon. While capsular charge does not have a large direct effect
on interactions with neutrophils, it can affect the 3-dimensional
stability of the capsule and the degree of encapsulation of the
bacteria [39,48]. Hence, capsular types with higher ratios of
charge to carbon may have physically larger and/or more
inhibitory capsules than those with lower ratios. Clearly, this
latter mechanism is not the entire explanation, because the neutral
type 14 capsule is relatively inhibitory (near the median in the
neutrophil-killing assay), but it may play a contributory role.
Whatever the mechanism(s) involved, our experimental manipu-
lations of polysaccharide production for a single serotype suggest
that capsular size itself affects interactions with the host even when
structure is held constant.
It has previously been noted that there is an inverse correlation
between carriage prevalence and invasiveness [6], and our findings
may also explain this phenomenon. Bacteria attached to the
epithelium tend to be less heavily encapsulated than unattached
pneumococci [49]. It has been suggested that direct interaction
with epithelial cells can promote invasion into underlying tissue
and blood, and capsule could disrupt this process [50,51]. As a
result, serotypes that avoid association with neutrophils might also
interact less with the epithelium and be less likely to invade. In
contrast, highly invasive serotypes, such as types 4 and 5, are
efficiently killed by neutrophils, but they might interact more
closely with the mucosal surface and be more likely to invade.
We have evaluated degree of encapsulation by measuring the
zone of inhibition of FITC-Dextran by the capsule. While this
method does not directly determine polysaccharide quantity, it
does provide a physiologically relevant measure of capsule
thickness, which could in turn affect accessibility of a number of
surface structures that could be recognized by neutrophils and
other immune effectors.
These findings raise several additional questions that should be
addressed in future studies. From the population-biological
perspective, a key question is: if metabolically costly capsules
reduce the ability of pneumococci to persist in the nasopharynx,
how do these capsular types persist in the population in the face of
competition from the metabolically less costly, more common
types? One possibility is that these types occupy a distinct
ecological niche. Such a niche could be a direct consequence of
these strains’ less pronounced capsule (perhaps allowing more
intimate association with the epithelium) or could be created by
the existence of serotype-specific immunity in some hosts, which
may be most prevalent against the most common types, providing
an advantage to the less common types to which fewer hosts are
naı ¨ve [29].
In summary, these results suggest that the epidemiologic
phenomena of serotype-specific prevalence in carriage and
possibly serotype replacement can be explained, in substantial
part, by bacterial characteristics measurable in vitro and further-
more by biochemical properties of the capsules themselves.
Previously, it had been observed that capsular types differ in their
epidemiological properties [4,6,16,17], but it was not clear to what
Figure 4. Relationship between capsule structure (carbon/
repeat unit) and carriage prevalence [44]. Capsule structure is
associated with prevalence both A) before introduction of conjugate
vaccine (r=20.80, p,0.001, excluding type 3) and B) after introduction
of vaccine (2004) among children in Massachusetts (r=20.90, p,0.05,
excluding type 3). Vaccine types are denoted by an open circle.
doi:10.1371/journal.ppat.1000476.g004
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or from the genetic backgrounds with which particular types –
especially the rare types, which tend to be highly clonal – are
associated. The hypothesis that capsule itself causes these
epidemiologic differences is strengthened by our findings that
the biochemical properties of the capsule predict epidemiologic
properties, and that mechanistic intermediates such as degree of
encapsulation and resistance to neutrophil killing, could be altered
by changing only the capsule.
Methods
Bacteria and cells
Blood was obtained from healthy volunteers according to a
protocol approved by the Office of Human Research Adminis-
tration at Harvard School of Public Health. Neutrophils were
isolated using a Histopaque 10771, 11191 gradient (Sigma-
Aldrich, St. Louis, MO) according to the manufacturer’s
instructions and used immediately.
Capsule-switch variants were constructed on the TIGR4 genetic
background [52] and were backcrossed at least three times, except
for serotypes 1 and 5, in which we could only accomplish one
backcross. The TIGR4 parent strain was itself backcrossed as a
control for the transformation procedure. The 603 capsular
variants were constructed with the same method and were all
backcrossed 3 times, except for type 6B, which was backcrossed
once as a transformation control. Nasopharyngeal clinical carriage
isolates (Table S2) were colony-purified prior to use. Strain 603
WT
is a type 6B invasive disease isolate [53], 603
cap- was constructed
by replacement of the capsule biosynthesis locus with the Janus
cassette, and 603
cap-:6B was constructed by transforming 603cap-
with genomic DNA from the parent strain, as described previously
[52,54]. All strains were grown in Todd Hewitt Broth with 0.5%
yeast extract (THY) (BD, Franklin Lakes, NJ) at 37u with 5% CO2
unless otherwise noted. In some cases, strains were grown in a
semi-defined minimal media [55] with 1000 U/mL catalase (MP
Biomedicals, Solon, OH) and 10 mM sugar.
Neutrophil surface killing assay
Neutrophil surface killing assays were performed as described
previously [31]. Briefly, bacteria were grown to mid-log phase and
frozen in THY/10% glycerol at 280u. On the day of the
experiment, bacteria were thawed and diluted to 5610
3 CFU/mL
in saline, and 10 mL of this suspension was spotted and allowed to
dry at room temperature on trypticase soy agar with 5%
defibrinated sheep blood (TSA II) (BD) with 10 replicates per
plate. Twenty microliters of neutrophils (2610
6 cells/mL) were
then overlaid, allowed to dry, and incubated overnight at 37u with
5% CO2. Percent survival was calculated by comparing killing of
each strain to a duplicate control plate with no neutrophils. All
experiments were repeated on several days with different frozen
lots of bacteria. The overall killing efficiency varied between
experiments, so we normalized the data by dividing percent
survival for each serotype by percent survival of type 9N to obtain
relative survival. The mean relative survival from at least two
independent experiments is presented unless otherwise stated. For
experiments comparing susceptibility to killing of isogenic capsule
switch variants and clinical isolates, the serogroup mean survival
was used.
FITC labeling of bacteria
Bacteria were grown to mid-log phase, washed in Hanks
balanced salt solution (HBSS) (Cellgro,Manassas, VA) with 1%
BSA, resuspended in FITC (Calbiochem, La Jolla, CA) (0.5 mg/
mL in HBSS/1%BSA) and incubated for 1 hour at 4u. The
bacteria were then washed twice and frozen in HBSS/1%BSA
with 10% glycerol. Staining was evaluated by flow cytometry to
ensure equivalent staining between strains.
Neutrophil association assay
To evaluate bacterial association with human neutrophils, we
developed a protocol based in part on Lee et al. [56]. In a 24-well
dish, we added 1 mL of blood agar base (BD) per well and allowed
it to solidify. FITC-labeled bacteria were then thawed, washed in
HBSS/1%BSA, and resuspended to 1610
8 CFU/mL. 50 mLo f
bacteria were added to each well, allowed to dry, and overlaid with
2.5610
5 neutrophils in 50 mL. After 20 minutes, 1 mL ice cold
HBSS/BSA was added to each well to harvest the neutrophils.
This mixture was then washed twice and fixed with 1% formalin
for 2 hours. Bacterial association with the neutrophils was assessed
by flow cytometry using a MoFlo flow cytometer (Dako
Cytomation, Denmark), and analysis was performed in Summit
v4.3 (Dako). The average relative fluorescence from two
independent experiments is presented.
Capsule size determination
The degree of encapsulation was determined by measuring the
zone of exclusion of FITC-dextran (2000 kDa, Sigma), based on
the method of Gates et al. [39]. Bacteria were grown overnight on
TSA II plates, swabbed into PBS, and 20 uL of bacteria were
mixed with 2 uL of a 10 mg/mL stock solution of FITC-dextran,
and used to create wet mounts with cover slips. The slides were
viewed on a Nikon Eclipse 80i with a 1006 objective, and
fluorescent images were captured with a Spot RT SE camera. The
images were analyzed with UTHSCSA ImageTool for Windows
v3.0 (University of Texas Health Science Center in San Antonio).
The area of FITC exclusion was determined, excluding chains and
clumps of cells. For each serotype, the mean area of 100–250 cells
was determined, and at least two images were collected from each
of at least two independently prepared slides. The capsular zone
was also visualized with India ink (Higgins, Oak Brook, IL) wet
mounts, as described previously [57]. When visualized with this
method, the bacterial body is surrounded by a bright halo, which
results from light diffraction, and this halo is surrounded by a zone
of clearance representing the capsule.
Polysaccharide quantification
Strains were grown in 10 mL semi-defined media with 10 mM
of glucose or fructose to mid-log phase and centrifuged. The
concentration was adjusted to OD620=0.6 in 1 mL, and the
suspension was lysed with 0.1% deoxycholate for 30 minutes and
incubated with 100 U mutanolysin overnight at 37u [58]. Cell-
associated type 19F capsular polysaccharide and phosphocholine
were quantified using an inhibition ELISA, based on the method
of Wessels et al [59]. Briefly, immulon-4 plates (Thermo Scientific,
Waltham, MA) were coated by incubating overnight with 5 mg/
mL cell wall polysaccharide (Statens Serum Institute, Copenha-
gen, Denmark) or 2 mg/mL type 19F capsular polysaccharide
(ATCC, Manassas, VA). TEPC15 (Sigma, mouse monoclonal IgA
directed against phosphocholine, 1:5000) or typing serum 19b
(Statens, 1:10,000) was mixed 1:1 with bacterial lysates or standard
dilutions of type 19F polysaccharide or cell wall, as appropriate.
TEPC15 was detected with goat anti-mouse IgA-HRP (Southern
Biotech, Birmingham, AL), and typing sera was detected with goat
anti-rabbit IgG-HRP (Southern Biotech) (1:8000). After develop-
ing with TMB substrate (KPL, Gaithersburg, MD) and addition of
1N HCl, the absorbance at 450nm was determined.
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5 week old C57/BL6J (Jackson Laboratories, Bar Harbor, ME)
were inoculated intranasally as described previously [31]. Briefly,
mice were challenged with 3.5610
6 CFU of strain TIGR4:14 and
3.5610
4 CFU of strain TIGR4:19F. At one week post-inoculation,
mice were euthanized by CO2 inhalation and tracheal washes
were collected from the nostrils. Colonization density of each
strain was determined by colony morphology and serotype was
confirmed by latex agglutination (Miravista Diagnostics, Indiana-
polis, IN). All animals were handled in strict accordance with good
animal practice, and all animal work was approved by the
Harvard Institutional Animal Care and Use Committee.
Biochemical information
Chemical structures of the capsular polysaccharide units were
obtained from Kamerling [60]. Structural data was not available
for serotypes 23A, 23B, 35F or 38, so they were excluded from the
analysis. Pathways for central metabolism were obtained from
www.biocyc.org [61]. Capsule-specific sugar precursor biosynthe-
sis pathways were obtained from Bentley et al [62] and Aanensen
et al [63]. For each serotype, we calculated the number of high-
energy bonds (ATP, UTP, CTP, TTP) and the number of carbons
required to generate each of the sugar precursors and subsequently
the number of carbons and high-energy bonds required to
generate one polysaccharide repeat unit (Table S1). We included
high energy bonds required for importing carbon and glutamine
and for converting monosaccharides to NDP-sugars. For energy
calculations, we ignored acetate and pyruvate, since they are
byproducts of normal metabolism.
Statistics
Carriage prevalence data were obtained from [12,17,44,64].
We calculated serotype frequency among carriage isolates and
averaged among the three studies to minimize the effect of
microepidemics. Only serotypes with frequency greater than 1%
among carriage isolates were included in correlations between
prevalence and biochemical properties.
Percent survival between strains was compared using either t-
tests or ANOVA, as appropriate. Non-parametric Spearman
correlation was used to evaluate the relationship between
epidemiologic measures and resistance to neutrophil mediated
killing or chemical composition of the capsule. For post-PCV7
correlations, serotypes targeted by the vaccine and those lacking
structural information were ignored. Linear regression was used to
evaluate the relationship between neutrophil-mediated killing of
isogenic capsule switch variants and clinical carriage isolates.
Analyses and graphing were performed in Graphpad Prism v5.0.
Supporting Information
Figure S1 Relationship between carriage prevalence and
resistance to neutrophil-mediated killing using isogenic capsule-
switch variants constructed in strain 603.
Found at: doi:10.1371/journal.ppat.1000476.s001 (0.03 MB PDF)
Figure S2 Representative images of TIGR4:19F, TIGR4:5
suspended in India ink.
Found at: doi:10.1371/journal.ppat.1000476.s002 (0.05 MB PDF)
Figure S3 Growth of TIGR4 isogenic capsule-switch variants in
fructose leads to increased susceptibility of heavily encapsulated
serotypes to neutrophil-mediated killing compared to the same
strains grown in glucose.
Found at: doi:10.1371/journal.ppat.1000476.s003 (0.04 MB PDF)
Figure S4 Relationship between serotype prevalence after
vaccination in Massachusetts (2004) and A) degree of encapsula-
tion (r=0.85, p,0.01), and B) survival from neutrophil-mediated
killing (r=0.63, n.s.).
Found at: doi:10.1371/journal.ppat.1000476.s004 (0.04 MB PDF)
Table S1 Number of carbons and high energy bonds required to
generate one polysaccharide repeat unit. For calculations of
energy/repeat unit, acetate and pyruvate were excluded because
they are byproducts of central metabolism. For calculations of
carbon/repeat unit, choline was also excluded since it is imported
into the cell and does not affect carbon utilization. Non-whole
numbers are due to non-stoichiometric acetylation or addition of
choline.
Found at: doi:10.1371/journal.ppat.1000476.s005 (0.05 MB PDF)
Table S2 Clinical isolates used in this study. Within a serogroup,
isolates of diverse multi-locus sequence types were chosen when
available.
Found at: doi:10.1371/journal.ppat.1000476.s006 (0.05 MB PDF)
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